With 0.8 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.01 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.3583 whereas the lowest price it dropped to was $0.2808. The 52-week range on PTPI shows that it touched its highest point at $2.27 and its lowest point at $0.22 during that stretch. It currently has a 1-year price target of $1.00. Beta for the stock currently stands at 1.95.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PTPI was down-trending over the past week, with a drop of -23.52%, but this was down by -12.09% over a month. Three-month performance dropped to -1.43% while six-month performance fell -31.61%. The stock lost -76.65% in the past year, while it has lost -21.17% so far this year.
Float and Shares Shorts:
At present, 10.01 million PTPI shares are outstanding with a float of 9.13 million shares on hand for trading. On 2024-10-31, short shares totaled 0.2 million, which was 199.00000000000003 higher than short shares on 1727654400. In addition to Mr. Fady Boctor M.B.A. as the firm’s President & Chief Commercial Officer, Mr. Mitchell S. Arnold M.B.A. serves as its VP of Finance & Chief Accounting Officer.
Institutional Ownership:
Through their ownership of 0.0229 of PTPI’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, PTPI reported revenue of $1576366.0 and operating income of -$2339748.0. The EBITDA in the recently reported quarter was -$1495671.0 and diluted EPS was -$0.53.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$2.13 being high and -$2.13 being low. For PTPI, this leads to a yearly average estimate of -$2.13. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
